Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 18Lymphoma, Non-Hodgkin 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Hodgkin Disease 11Lymphoma, Large B-Cell, Diffuse 9Central Nervous System Neoplasms 9Leukemia, Myeloid, Acute 8Neuroblastoma 7Multiple Myeloma 7Leukemia 7Brain Neoplasms 7Small Cell Lung Carcinoma 6Sarcoma 6Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Mantle-Cell 5Lymphoma, Follicular 5Leukemia, Lymphocytic, Chronic, B-Cell 5Lymphoma, B-Cell, Marginal Zone 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Testicular Neoplasms 3Teratoma 3Rhabdoid Tumor 3Medulloblastoma 3Lung Neoplasms 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Testicular Germ Cell Tumor 2Rhabdomyosarcoma 2Recurrence 2

Interventions

Rituximab 47Cyclophosphamide 26fludarabine 13ibrutinib 12Doxorubicin 11Vincristine 10Etoposide 10Cytarabine 10Prednisone 9Bortezomib 9pembrolizumab 7fludarabine phosphate 6Lenalidomide 6Inotuzumab Ozogamicin 6obinutuzumab 5Mycophenolic Acid 5Melphalan 5Carmustine 5tositumomab I-131 4ibritumomab tiuxetan 4Tacrolimus 4Prednisolone 4Methotrexate 4Gemcitabine 4Bendamustine Hydrochloride 4Antilymphocyte Serum 4tocilizumab 3tazemetostat 3Whole-Body Irradiation 3Vorinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, B-Cell × etoposide phosphate × Clear all
NCT01458366 2025-04-30

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

Thomas Jefferson University

Phase 1/2 Completed
38 enrolled 17 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡